Form 8-K





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2015



BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)




Delaware   000-26727   68-0397820

(State or other jurisdiction of

incorporation or organization)



File Number)


(IRS Employer

Identification No.)


770 Lindaro Street, San Rafael, California   94901
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (415) 506-6700

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 1, 2015, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of BioMarin Pharmaceutical Inc. (the “Company”) approved a supplemental cash bonus of $50,000 for G. Eric Davis, the Company’s Senior Vice President and General Counsel, to be paid in March 2015. The Compensation Committee awarded Mr. Davis this bonus to reward him for his extraordinary efforts in connection with the Company’s previously disclosed acquisition of Prosensa Holding N.V., a public limited liability company organized under the laws of The Netherlands.


- 2 -


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


BioMarin Pharmaceutical Inc.,

a Delaware corporation

Date: March 6, 2015 By:

/s/ G. Eric Davis

G. Eric Davis
Senior Vice President, General Counsel


- 3 -